UPDATE 2-Supernus Pharma's ADHD treatment meets main goal in two studies

Supernus Pharmaceuticals Inc on Thursday said its experimental treatment for attention deficit hyperactivity disorder met the main goal of reducing symptoms in affected children from six to 11 years of age in two late-stage studies.